DDInter822 DDInter1016
Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed. Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. Aberrant of Hh signaling is one
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in patients with cirrhosis.[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.
Glasdegib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Glasdegib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Glasdegib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Glasdegib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levosalbutamol
Glasdegib {u} may lead to a major life threatening interaction when taken with {v} Bedaquiline
Glasdegib {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Glasdegib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Glasdegib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Glasdegib may lead to a major life threatening interaction when taken with Bedaquiline
Glasdegib may lead to a major life threatening interaction when taken with Ivosidenib